Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.

Breast cancer research : BCR - 1 Jan 2011

Miller Todd W, Rexer Brent N, Garrett Joan T, Arteaga Carlos L

Abstract excerpt

Mutations in genes that constitute the phosphatidylinositol 3-kinase (PI3K) pathway occur in >70% of breast cancers. Clinical and experimental evidence suggest that PI3K pathway activation promotes resistance to some of the current breast cancer therapies. PI3K is a major signaling hub downstream of human epidermal growth factor receptor (HER)2 and other receptor tyrosine kinases. PI3K activates AKT,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Enzyme Inhibitors

Share to Phosphatidylinositol 3-Kinases

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Source

Open in PubMed Open full text

Identifiers

PMID: 22114931
DOI: 10.1186/bcr3039
PMCID: PMC3315683

Genes

PDK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.PMID 22114931Read ↗

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.Semantic proximity Read ↗

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.Semantic proximity Read ↗

Overview of the relevance of PI3K pathway in HR-positive breast cancerSemantic proximity Read ↗

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current AchievementsSemantic proximity Read ↗

Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.Semantic proximity Read ↗

Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors.Semantic proximity Read ↗

PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.Semantic proximity Read ↗

The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.Semantic proximity Read ↗

Deciphering the role of phosphatidylinositol 3-kinase mutations in human epidermal growth factor receptor 2-positive breast cancer.Semantic proximity Read ↗

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesSemantic proximity Read ↗

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.Semantic proximity Read ↗

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.